<DOC>
	<DOCNO>NCT02857010</DOCNO>
	<brief_summary>Double-blind placebo randomize control trial evaluate clinical efficacy allogenic bone marrow derive mesenchymal stem cell cirrhotic patient acute-on-chronic liver failure</brief_summary>
	<brief_title>Allogenic Bone Marrow Mesenchymal Stem Cell Therapy Acute-on-chronic Liver Failure</brief_title>
	<detailed_description>Introduction : The important cause death patient cirrhosis development Acute-on-Chronic Liver Failure ( ACLF ) , syndrome recently redefine high mortality . The effective treatment ACLF liver transplantation . However , available organ limit . Other treatment , artificial liver support system , improve survival . ACLF characterize increase systemic inflammatory state together impair liver regeneration lead multiorgan failure . Mesenchymal stem cell ( MSC ) therapy attractive strategy ACLF owe immunomodulatory regenerative property cell . Aim : To investigate effect allogeneic bone marrow MSCs transplantation liver organ function systemic inflammation patient ACLF . Altruist bone marrow donor source MSCs . Design methodology : randomize , double-blind phase I placebo-controlled trial aim compare placebo ( solution without cell ) MSCs ( 4 dose 2 x 106/kg administered day 1 , 4 , 11 18 ) . Thirty patient , 15 per group include . ACLF define CLIF SOFA score patient stratify accord severity . Outcomes evaluate : 1 ) Organ function ( CLIF SOFA CLIF-C ACLF score ) ; 2 ) Liver ( Child-Pugh MELD score , serum bile acid , ammonia lactate level ) , circulatory ( systemic splanchnic hemodynamics , renin , noradrenalin ) endothelial function ( nitric oxide , von Willebrand factor ) ; 3 Inflammatory response ( serum cytokine panel transcriptomic analysis monocyte polymorphonuclear cell peripheral blood ) ; 4 ) Survival 28 day , 3 12 month ; 5 ) Safety . Expected result : Therapy MSCs could beneficial effect evolution patient ACLF ( modulation inflammatory response improvement liver extra-hepatic organ function ) could translate improvement short-term survival .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<mesh_term>Liver Failure , Acute</mesh_term>
	<criteria>Liver cirrhosis ACLF grade 1 , 2 3 ( Canonic criterion ) Signed informed consent Acute subacute liver failure without cirrhosis ACLF grade 1 response medical therapy Evidence current malignancy include hepatocellular carcinoma ( grade ) alphafetoprotein &gt; 400 ng/ml Previous personal history malignancy ( active complete remission ) familiar history hereditary cancer . Moderate severe chronic heart failure ( NYHA IIIIV ) Renal replacement therapy Severe chronic pulmonary disease ( GOLD IIIIV ) Gastrointestinal bleeding last 5 day Previous liver transplantation Immunosuppressive therapy Extrahepatic cholestasis HIV infection Pregnant breastfeed woman Premenopausal woman child bear potential practicing acceptable method birth control . Participation investigational trial last 3 month Active addition illegal drug Refusal participate Patients provide prior inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>